Development and validation of a nomogram for evaluating the prognosis of immunotherapy plus antiangiogenic therapy in non-small cell lung cancer

BACKGROUND: With the combination therapy of PD-1/PD-L1 antibody and antiangiogenic drugs used widely in clinic, a novel method to estimate the prognosis of patients is needed. We aimed to develop a nomogram to examine prognosis of anti-PD-1/PD-L1 antibody plus bevacizumab in non-small cell lung canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Hao, Chen, Yao, Weng, Xuezi, Li, Sirou, Zhang, Lin, Chen, Peisong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394085/
https://www.ncbi.nlm.nih.gov/pubmed/35989349
http://dx.doi.org/10.1186/s12935-022-02675-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394085/
https://www.ncbi.nlm.nih.gov/pubmed/35989349
http://dx.doi.org/10.1186/s12935-022-02675-y

Ejemplares similares